GlassScriptPhysician profile
Thomas E Scarborough
NPI 1235194200
$3,329.43
in general payments reported to CMS, 2019-2025
22 companies · $232 in 2025
The $232 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $440 · 2020: $570 · 2021: $661 · 2022: $532 · 2023: $545 · 2024: $350 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,092 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,092.46 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,168.62 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Genzyme Corporation | $432.03 | 2019-2024 | |
| Pfizer INC. | $364.05 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $262.13 | 2019-2024 | Dupixent |
| Csl Behring | $182.97 | 2022-2025 | Haegarda, Hizentra |
| Glaxosmithkline, LLC. | $158.94 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Pharming Healthcare, INC. | $110.18 | 2019-2024 | Ruconest |
| Takeda Pharmaceuticals U.S.A., INC. | $98.99 | 2020-2022 | |
| Blueprint Medicines Corporation | $87.34 | 2023-2025 | Ayvakit |
| Biocryst US Sales Co., LLC | $68.59 | 2022-2024 | Orladeyo |
| Genentech USA, INC. | $50.52 | 2021 | |
| Horizon Therapeutics Plc | $50.14 | 2021-2023 | Actimmune |
| Grifols USA, LLC | $50.01 | 2022-2023 | Xembify |
| Amgen INC. | $49.35 | 2023-2025 | Tezspire |
| Ars Pharmaceuticals Operations, INC. | $32.01 | 2025 | Neffy |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $30.34 | 2022 | |
| Novartis Pharmaceuticals Corporation | $27.95 | 2025 | |
| Shire North American Group INC | $25.57 | 2019 | |
| Uswm, LLC | $24.00 | 2021 | |
| Kaleo, INC. | $20.28 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $18.00 | 2021 | |
| Verona Pharma, INC. | $17.42 | 2025 | Ohtuvayre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Scarborough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.